Cargando…
Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis
Non-alcoholic fatty liver disease (NAFLD) is associated with a substantial increased risk of atherosclerotic cardiovascular disease (ASCVD), which is partly related to dyslipidemia and low HDL-C level. The cardioprotective activity of HDL in the body is closely connected to its role in promoting cho...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076293/ https://www.ncbi.nlm.nih.gov/pubmed/30076407 http://dx.doi.org/10.1038/s41598-018-29639-5 |
_version_ | 1783344687571009536 |
---|---|
author | Fadaei, Reza Poustchi, Hossein Meshkani, Reza Moradi, Nariman Golmohammadi, Taghi Merat, Shahin |
author_facet | Fadaei, Reza Poustchi, Hossein Meshkani, Reza Moradi, Nariman Golmohammadi, Taghi Merat, Shahin |
author_sort | Fadaei, Reza |
collection | PubMed |
description | Non-alcoholic fatty liver disease (NAFLD) is associated with a substantial increased risk of atherosclerotic cardiovascular disease (ASCVD), which is partly related to dyslipidemia and low HDL-C level. The cardioprotective activity of HDL in the body is closely connected to its role in promoting cholesterol efflux, which is determined by cholesterol efflux capacity (CEC). Hitherto, the role of HDL, as defined by CEC has not been assessed in NAFLD patients. In this research study, we present the results of a study of cAMP-treated J774 CEC and THP-1 macrophage CEC in ApoB-depleted plasma of 55 newly diagnosed NAFLD patients and 30 controls. Circulating levels of ApoA-I, ApoB, preβ-HDL, plasma activity of CETP, PLTP, LCAT and carotid intima-media thickness (cIMT) were estimated. cAMP-treated J774 and THP-1 macrophage CEC were found to be significantly lower in NAFLD patients compared to controls (P < 0.001 and P = 0.003, respectively). In addition, it was discovered that both ApoA-I and preβ1-HDL were significantly lower in NAFLD patients (P < 0.001). Furthermore, cAMP-treated J774 CEC showed independent negative correlation with cIMT, as well as the presence of atherosclerotic plaque in NAFLD patients. In conclusion, our findings showed that HDL CEC was suppressed in NAFLD patients, and impaired cAMP-treated J774 CEC was an independent risk factor for subclinical atherosclerosis in NAFLD patients, suggesting that impaired HDL functions as an independent risk factor for atherosclerosis in NAFLD. |
format | Online Article Text |
id | pubmed-6076293 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-60762932018-08-08 Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis Fadaei, Reza Poustchi, Hossein Meshkani, Reza Moradi, Nariman Golmohammadi, Taghi Merat, Shahin Sci Rep Article Non-alcoholic fatty liver disease (NAFLD) is associated with a substantial increased risk of atherosclerotic cardiovascular disease (ASCVD), which is partly related to dyslipidemia and low HDL-C level. The cardioprotective activity of HDL in the body is closely connected to its role in promoting cholesterol efflux, which is determined by cholesterol efflux capacity (CEC). Hitherto, the role of HDL, as defined by CEC has not been assessed in NAFLD patients. In this research study, we present the results of a study of cAMP-treated J774 CEC and THP-1 macrophage CEC in ApoB-depleted plasma of 55 newly diagnosed NAFLD patients and 30 controls. Circulating levels of ApoA-I, ApoB, preβ-HDL, plasma activity of CETP, PLTP, LCAT and carotid intima-media thickness (cIMT) were estimated. cAMP-treated J774 and THP-1 macrophage CEC were found to be significantly lower in NAFLD patients compared to controls (P < 0.001 and P = 0.003, respectively). In addition, it was discovered that both ApoA-I and preβ1-HDL were significantly lower in NAFLD patients (P < 0.001). Furthermore, cAMP-treated J774 CEC showed independent negative correlation with cIMT, as well as the presence of atherosclerotic plaque in NAFLD patients. In conclusion, our findings showed that HDL CEC was suppressed in NAFLD patients, and impaired cAMP-treated J774 CEC was an independent risk factor for subclinical atherosclerosis in NAFLD patients, suggesting that impaired HDL functions as an independent risk factor for atherosclerosis in NAFLD. Nature Publishing Group UK 2018-08-03 /pmc/articles/PMC6076293/ /pubmed/30076407 http://dx.doi.org/10.1038/s41598-018-29639-5 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Fadaei, Reza Poustchi, Hossein Meshkani, Reza Moradi, Nariman Golmohammadi, Taghi Merat, Shahin Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
title | Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
title_full | Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
title_fullStr | Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
title_full_unstemmed | Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
title_short | Impaired HDL cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
title_sort | impaired hdl cholesterol efflux capacity in patients with non-alcoholic fatty liver disease is associated with subclinical atherosclerosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6076293/ https://www.ncbi.nlm.nih.gov/pubmed/30076407 http://dx.doi.org/10.1038/s41598-018-29639-5 |
work_keys_str_mv | AT fadaeireza impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT poustchihossein impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT meshkanireza impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT moradinariman impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT golmohammaditaghi impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis AT meratshahin impairedhdlcholesteroleffluxcapacityinpatientswithnonalcoholicfattyliverdiseaseisassociatedwithsubclinicalatherosclerosis |